Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000700
Status:
COMPLETED
Last Update Posted:
2021-11-04
First Post:
1999-11-02
Brief Title:
A Multi-Center Clinical Trial To Evaluate Azidothymidine AZT in the Treatment of Human Immunodeficiency Virus HIV Infection in Patients With AIDS Post First Episode PCP
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
A Multi-Center Clinical Trial To Evaluate Azidothymidine AZT in the Treatment of Human Immunodeficiency Virus HIV Infection in Patients With AIDS Post First Episode PCP
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To examine the dose of zidovudine AZT that was used in the first placebo-controlled study of AZT in AIDS patients as well as a lower dose of AZT in order to determine if the lower dose results in less harmful side effects while still being effective Previous studies have shown the effectiveness of AZT in AIDS therapy AZT has been effective in test tube studies at varying doses There is a need to see if lower doses result in effective therapy with less harmful side effects
Detailed Description:
Previous studies have shown the effectiveness of AZT in AIDS therapy AZT has been effective in test tube studies at varying doses There is a need to see if lower doses result in effective therapy with less harmful side effects
Patients are assigned at random to one of two treatment programs 1 1 dose of AZT given orally PO for 6 doses per day 2 2 doses of AZT PO for 4 weeks followed by 1 dose PO for the remainder of the trial
Patients are assigned at random to one of two treatment programs 1 1 dose of AZT given orally PO for 6 doses per day 2 2 doses of AZT PO for 4 weeks followed by 1 dose PO for the remainder of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 10978 | REGISTRY | DAIDS ES Registry Number | None |